DeepMed Research

SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Phase 3

Active, not recruiting

Conditions: Hemophilia A, Severe

Interventions: Drug: Efanesoctocog alfa

First Posted Date: 2023-04-18

Last Posted Date: 2025-03-17

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 93

Registration Number: NCT05817812

Locations: 🇬🇧
Investigational Site, Oxford, United Kingdom

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Phase 3

Active, not recruiting

Conditions: Still's Disease, Juvenile Onset
Still's Disease, Adult-Onset

Interventions: Drug: Placebo
Drug: Anakinra

First Posted Date: 2023-04-14

Last Posted Date: 2025-03-05

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 15

Registration Number: NCT05814159

Locations: 🇯🇵
Fukushima Medical University Hospital, Fukushima-shi, Fukushima, Japan
🇯🇵
Kobe University Hospital, Kobe city, Hyogo, Japan
🇯🇵
Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan

and more 5 locations

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recruiting

Conditions: Paroxysmal Nocturnal Hemoglobinuria

First Posted Date: 2023-03-20

Last Posted Date: 2025-05-14

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 200

Registration Number: NCT05776472

Locations: 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺
Calvary Mater Newcastle, Waratah, New South Wales, Australia
🇦🇺
Sunshine Coast University Hospital, Birtinya, Queensland, Australia

and more 72 locations

A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

Phase 4

Active, not recruiting

Conditions: Primary Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Emapalumab-Lzsg 5 MG/ML [Gamifant]

First Posted Date: 2023-02-24

Last Posted Date: 2024-10-15

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 13

Registration Number: NCT05744063

Locations: 🇨🇳
Swedish Orphan Biovitrum Research site, Zhengzhou, China

Evaluate the PK Efficacy Safety and Tolerability of Pegcetacoplan in Patients With Thrombotic Microangiopathy

Phase 2

Completed

Conditions: Transplant-Associated Thrombotic Microangiopathy

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-12-08

Last Posted Date: 2024-12-19

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 12

Registration Number: NCT05148299

Locations: 🇬🇷
University General Hospital "Attikon", Athens, Chaidari, Greece
🇫🇷
CHU de Saint-Etienne, Saint-Priest-en-Jarez, France
🇬🇷
General Hospital of Thessaloniki "G. Papanikolaou", Hematology Department - BMT Unit, Thessaloníki, Greece

and more 11 locations

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Phase 3

Suspended

Conditions: Cold Agglutinin Disease

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-10-27

Last Posted Date: 2024-04-11

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 57

Registration Number: NCT05096403

Locations: 🇬🇪
Ltd M. Zodelava Hematology Centre, Tbilisi, Georgia
🇬🇧
Churchill Hospital, Oxford, United Kingdom
🇧🇪
CHU de Liège, Liège, Belgium

and more 41 locations

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Phase 3

Active, not recruiting

Conditions: Macrophage Activation Syndrome
SJIA
MAS
Secondary Hemophagocytic Lymphohistiocytosis
Still Disease
Systemic Lupus Erythematosus
AOSD

Interventions: Drug: Emapalumab

First Posted Date: 2021-08-12

Last Posted Date: 2024-10-15

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 41

Registration Number: NCT05001737

Locations: 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇨🇳
Children's Hospital of Fudan University, Shanghai, China
🇳🇱
UMC Utrecht, Utrecht, Netherlands

and more 43 locations

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

Active, not recruiting

Conditions: Immune Thrombocytopenia
ITP

Interventions: Drug: Avatrombopag

First Posted Date: 2021-06-29

Last Posted Date: 2025-03-21

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 200

Registration Number: NCT04943042

Locations: 🇨🇭
Swedish Orphan Biovitrum Research Site 802, Basel, Switzerland
🇪🇸
Swedish Orphan Biovitrum Research Site 606, Oviedo, Spain
🇩🇪
Swedish Orphan Biovitrum Research Site 103, Bad Homburg, Germany

and more 52 locations

A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.

Phase 1

Completed

Conditions: Rare Diseases

Interventions: Drug: NI-0501
Drug: Saline

First Posted Date: 2021-02-21

Last Posted Date: 2023-11-30

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 8

Registration Number: NCT04765553

Locations: 🇯🇵
P-One Clinic, Tokyo, Japan

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)

Completed

Conditions: Hemophilia B
Hemophilia A

First Posted Date: 2021-02-01

Last Posted Date: 2022-08-31

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 180

Registration Number: NCT04731701

Locations: 🇫🇷
Swedish Orphan Biovitrum Clinical site, Toulouse, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy